|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||19.81 - 20.14|
|52 Week Range||10.85 - 35.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||18.73|
Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.
A trial under way in federal court in Philadelphia is testing the power of U.S. competition regulators to crack down on drug makers’ alleged moves to thwart the sale of low-cost generics.
Berkshire Hathaway Inc. (NYSE:BRK.B) filed its 13F with the SEC on Valentine’s day and revealed a huge purchase in shares of Apple Inc (NASDAQ: AAPL ). What investors aren't talking about is the six other ...
This post is brought to you by Finbox.io . Sign up for your completely FREE trial today! Berkshire Hathaway filed its 13F with the SEC on Valentine’s day and revealed a huge purchase in shares of Apple Inc (Nasdaq: AAPL). What investors aren’t ...
Teva Pharmaceutical Industries Ltd., today announced the exclusive launch of two strengths of a generic version of Solodyn®1 Extended Release Tablets, 65 and 115 mg, in the U.S.
GlaxoSmithKline’s (GSK) Pharmaceuticals business includes respiratory products, immuno-inflammation products, HIV products, and its established products portfolio. The chart below illustrates the revenues for its Pharmaceuticals business since 1Q16. The Pharmaceuticals segment reported revenues of ~4.5 billion pounds in 4Q17, driven by the increase in sales of its HIV products (Triumeq and Tivicay). It was also driven by growth in the sales of its new respiratory products (Ellipta portfolio and Nucala).
United Therapeutics has settled patent litigation over a $157 million drug. The company (UTHR) reached an agreement with Actavis Laboratories FL, which is a subsidiary of generic giant Teva Pharmaceuticals, that resolves litigation over certain patents related to one of United Therapeutics' pulmonary arterial hypertension drugs: Orenitram. The settlement agreement allows Actavis to begin manufacturing and commercializing a generic version of the drug in June 2027 or potentially earlier under some circumstances. However, United Therapeutics noted that the agreement doesn't allow Actavis to manufacture generic versions of other products like Tyvaso or Remodulin.
The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.
Teva Pharmaceutical Industries Ltd. announced today that QVAR® RediHaler™ Inhalation Aerosol is now commercially available to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S.
After Berkshire Hathaway (BRK) disclosed its investment of $358 million in Teva Pharmaceuticals (TEVA) on February 14, 2018, in a regulatory filing at the end of 4Q17, Wall Street analysts have had a lot to say about the investment. Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day. The PowerShares International Dividend Achievers Portfolio (PID) rose ~1.3% on February 15, 2018.
Warren Buffett has the Midas touch: Teva soared after 13F filings showed Berkshire invested $358 million in the drug maker.
On February 15, 2018, Teva Pharmaceutical (TEVA) stock registered a rise of ~10.5% in pre-market trading on the disclosure of Berkshire Hathaway’s (BRK) investment of $358 million in the stock at the end of 4Q17. Berkshire Hathaway’s investment in Teva bodes well for Teva investors. Given that Berkshire Hathaway’s investments are based on founder Warren Buffet’s value investing strategy, Teva is now seen as a fundamental value investment.
NEW YORK, NY / ACCESSWIRE / February 16, 2018 / Ironwood Pharmaceuticals was a big winner on Thursday after reporting better than expected fourth quarter results. Shares of Teva also scored big gains after ...
Show of hands: Who bought the dip last Friday morning when the S&P 500 hit its 200-day moving average? Because if you did, you look like a genius. The S&P 500 gained 1.2% to 2731.20 today, while the Dow Jones Industrial Average rose 306.88 points, or 1.2%, to 25,200.37. The Nasdaq Composite climbed 1.6% to 7256.43.
Stocks that moved substantially or traded heavily Thursday: Cisco Systems Inc., up $1.99 to $44.08 The technology company had a solid second quarter and said it will buy back $25 billion in stock. Teva ...